Financial News
Biogen beats expectations, hikes outlook as Alzheimer's drug Leqembi and other new products gain traction
August 01, 2024 at 06:56 AM EDT
Uptake of Biogen's breakthrough Alzheimer's drug, Leqembi, appears to be picking up, with roughly $40 million in sales for the quarter.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
